

# Jie He

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/792/publications.pdf>

Version: 2024-02-01

280  
papers

12,800  
citations

50276

46  
h-index

36028

97  
g-index

295  
all docs

295  
docs citations

295  
times ranked

13719  
citing authors

#	ARTICLE	IF	CITATIONS
1	The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma. <i>Genes and Diseases</i> , 2022, 9, 415-428.	3.4	5
2	Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 943-954.	2.5	21
3	Outcomes and experience of anatomical partial lobectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 637-647.e1.	0.8	9
4	Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. <i>Cancer Science</i> , 2022, 113, 648-659.	3.9	16
5	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. <i>Npj Precision Oncology</i> , 2022, 6, 2.	5.4	17
6	Pan-cancer analysis combined with experiments explores the oncogenic role of spindle apparatus coiled-coil protein 1 (SPDL1). <i>Cancer Cell International</i> , 2022, 22, 49.	4.1	3
7	Methionine oxidation of CLK4 promotes the metabolic switch and redox homeostasis in esophageal carcinoma via inhibiting MITF selective autophagy. <i>Clinical and Translational Medicine</i> , 2022, 12, e719.	4.0	8
8	<scp>BMI</scp> changes and the risk of lung cancer in male never-smokers: A prospective cohort study. <i>Cancer Medicine</i> , 2022, 11, 1336-1346.	2.8	8
9	Lung cancer risk prediction models based on pulmonary nodules: A systematic review. <i>Thoracic Cancer</i> , 2022, 13, 664-677.	1.9	16
10	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2022, 12, 843299.	2.8	6
11	Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2341-2354.	4.2	26
12	Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 783495.	4.8	13
13	One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 378-391.	10.7	69
14	Choline Kinase Alpha2 Promotes Lipid Droplet Lipolysis in Non-Small-Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 848483.	2.8	1
15	Sintilimab for the treatment of non-small cell lung cancer. <i>Biomarker Research</i> , 2022, 10, 23.	6.8	16
16	National Cancer Data Linkage Platform of China: Design, Methods, and Application.. <i>China CDC Weekly</i> , 2022, 4, 271-275.	2.3	0
17	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. <i>BMC Medicine</i> , 2022, 20, 187.	5.5	28
18	Mapping of Lymph Node Metastasis From Thoracic Esophageal Cancer: A Retrospective Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5681-5688.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 909-920.	1.1	28
20	The potential role of N7-methylguanosine (m7G) in cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, 63.	17.0	94
21	Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	2
22	<sc>PSC</sc> subtyping based on <sc>TTF</sc> and p40 expression reveals distinct molecular characteristics and therapeutic strategies. <i>International Journal of Cancer</i> , 2022, 151, 717-729.	5.1	2
23	Lipid metabolism-related lncRNA <i>SLC25A21-AS1</i> promotes the progression of oesophageal squamous cell carcinoma by regulating the NPM1/c-Myc axis and <i>SLC25A21</i> expression. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	13
24	Abstract 5349: Single-cell analysis sheds light on the resistance mechanisms of a novel pan-HER inhibitor, pyrotinib, in non-small cell lung cancer. <i>Cancer Research</i> , 2022, 82, 5349-5349.	0.9	0
25	Abstract 5692: Tissue specificity of chromosome aneuploidy correlates with BRCA-associated cancer risk. <i>Cancer Research</i> , 2022, 82, 5692-5692.	0.9	0
26	Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, e16040-e16040.	1.6	0
27	<i>KRAS</i> G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. <i>Cancer Communications</i> , 2022, 42, 828-847.	9.2	29
28	An initial screening strategy based on epidemiologic information in esophageal cancer screening: a prospective evaluation in a community-based cancer screening cohort in rural China. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 110-118.e2.	1.0	12
29	Selection of high-risk individuals for esophageal cancer screening: A prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China. <i>International Journal of Cancer</i> , 2021, 148, 329-339.	5.1	36
30	Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort. <i>Annals of Surgical Oncology</i> , 2021, 28, 3941-3950.	1.5	69
31	Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma. <i>European Journal of Cancer</i> , 2021, 142, 123-131.	2.8	11
32	Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?. <i>Cancer Communications</i> , 2021, 41, 3-15.	9.2	10
33	Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study. <i>Clinical Lung Cancer</i> , 2021, 22, e201-e210.	2.6	19
34	Health-related quality of life of patients with colorectal neoplasms in China: A multicenter cross-sectional survey. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1197-1207.	2.8	5
35	MiRACLE: an individual-specific approach to improve microRNA-target prediction based on a random contact model. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	1
36	The prognostic value of tumor deposits and the impact on the TNM classification system in esophageal cancer patients. <i>Journal of Surgical Oncology</i> , 2021, 123, 891-903.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110069.	3.2	4
38	The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 562-568.	3.0	7
39	Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. <i>Cancer Medicine</i> , 2021, 10, 1681-1689.	2.8	39
40	PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF- $\kappa$ B/IL8 pathway. <i>Cell Death Discovery</i> , 2021, 7, 32.	4.7	38
41	Prognostic Impact of IGF2BP3 Expression in Patients with Surgically Resected Lung Adenocarcinoma. <i>DNA and Cell Biology</i> , 2021, 40, 316-331.	1.9	21
42	Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2367-2378.	4.2	7
43	Prognostic Impact of PCK1 Protein Kinase Activity-Dependent Nuclear SREBP1 Activation in Non-Small-Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 561247.	2.8	13
44	A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 651406.	3.7	30
45	Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 4893-4904.	1.5	12
46	Comprehensive Analysis of Ferroptosis Regulators in Lung Adenocarcinomas Identifies Prognostic and Immunotherapy-Related Biomarkers. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 587436.	3.5	13
47	Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1734-1746.	2.8	8
48	Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3651-3667.	4.2	14
49	Association between pre-diagnostic serum albumin and cancer risk: Results from a prospective population-based study. <i>Cancer Medicine</i> , 2021, 10, 4054-4065.	2.8	20
50	Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. <i>Targeted Oncology</i> , 2021, 16, 425-434.	3.6	16
51	Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC. <i>Journal of Clinical Oncology</i> , 2021, 39, 8522-8522.	1.6	4
52	Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade. <i>Journal of Clinical Oncology</i> , 2021, 39, 9063-9063.	1.6	0
53	A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?. <i>Cancer Medicine</i> , 2021, 10, 3437-3448.	2.8	3
54	Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 669750.	4.8	45

#	ARTICLE	IF	CITATIONS
55	WNT/ $\beta$ -catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 462.	6.3	75
56	Patterns and trends of cancer incidence in children and adolescents in China, 2011–2015: A population-based cancer registry study. <i>Cancer Medicine</i> , 2021, 10, 4575-4586.	2.8	9
57	Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones. <i>BMC Cancer</i> , 2021, 21, 690.	2.6	8
58	Tumor-infiltrating CD8 <sup>+</sup> T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited-stage small cell esophageal carcinoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e456.	4.0	3
59	Effects of cancer treatment on household impoverishment: a multicentre cross-sectional study in China. <i>BMJ Open</i> , 2021, 11, e044322.	1.9	7
60	Development and validation of m6A RNA methylation regulators-based signature in lung adenocarcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2128-2130.	2.3	3
61	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. <i>Nature Communications</i> , 2021, 12, 3785.	12.8	16
62	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. <i>Nature Communications</i> , 2021, 12, 3803.	12.8	74
63	Improved esophageal squamous cell carcinoma screening effectiveness by risk-stratified endoscopic screening: evidence from high-risk areas in China. <i>Cancer Communications</i> , 2021, 41, 715-725.	9.2	8
64	Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1. <i>Translational Lung Cancer Research</i> , 2021, 10, 3155-3172.	2.8	32
65	Catastrophic Health Expenditure and Its Determinants Among Households With Breast Cancer Patients in China: A Multicentre, Cross-Sectional Survey. <i>Frontiers in Public Health</i> , 2021, 9, 704700.	2.7	26
66	Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 1093-1093.	1.7	3
67	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. <i>Lung Cancer</i> , 2021, 157, 116-123.	2.0	4
68	Ubiquitination Destabilizes Protein Sphingosine Kinase 2 to Regulate Glioma Malignancy. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 660354.	3.7	5
69	LAMC1 upregulation via TGF $\beta$ 2 induces inflammatory cancer-associated fibroblasts in esophageal squamous cell carcinoma via NF $\kappa$ B–CXCL1–STAT3. <i>Molecular Oncology</i> , 2021, 15, 3125-3146.	4.6	26
70	Abstract 772: A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic responses prediction in patients with stage I lung adenocarcinoma. , 2021, , .		0
71	Risk factors for gastric cancer: a large-scale, population-based case-control study. <i>Chinese Medical Journal</i> , 2021, 134, 1952-1958.	2.3	16
72	S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. <i>Clinical and Translational Medicine</i> , 2021, 11, e459.	4.0	26

#	ARTICLE	IF	CITATIONS
73	Integrative analysis and experiments to explore angiogenesis regulators correlated with poor prognosis, immune infiltration and cancer progression in lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2021, 19, 361.	4.4	7
74	Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 53.	1.5	7
75	Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA. <i>Cancer Genetics</i> , 2021, 258-259, 93-100.	0.4	2
76	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-“Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2021, 7, 1178.	7.1	128
77	Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 314.	17.1	2
78	Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1618-1630.	2.7	15
79	The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance. <i>Molecular Cancer</i> , 2021, 20, 122.	19.2	6
80	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 1265-1274.	10.7	102
81	RNA N <sup>6</sup> -methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential. <i>Clinical and Translational Medicine</i> , 2021, 11, e525.	4.0	18
82	553Stage at diagnosis for six major cancers in China with comparison to the United States. <i>International Journal of Epidemiology</i> , 2021, 50, .	1.9	0
83	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	2.8	12
84	The Landscape of Cell and Gene Therapies for Solid Tumors. <i>Cancer Cell</i> , 2021, 39, 7-8.	16.8	18
85	A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 734-749.	3.0	2
86	Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 18-31.	2.8	8
87	Menstrual factors, reproductive history, and risk of lung cancer: a multi-center population-based cohort study in Chinese females. <i>Translational Lung Cancer Research</i> , 2021, 10, 3912-3928.	2.8	4
88	Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study. <i>Journal of Thoracic Disease</i> , 2021, 13, 5604-5616.	1.4	6
89	TGF- $\beta$ -induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2. <i>Cell Death and Disease</i> , 2021, 12, 901.	6.3	17
90	A Multi-Center Validated Subtyping Model of Esophageal Cancer Based on Three Metabolism-Related Genes. <i>Frontiers in Oncology</i> , 2021, 11, 772145.	2.8	1

#	ARTICLE	IF	CITATIONS
91	H3K36 trimethylation-mediated biological functions in cancer. <i>Clinical Epigenetics</i> , 2021, 13, 199.	4.1	25
92	The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors. <i>Aging</i> , 2021, 13, 1383-1409.	3.1	9
93	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743724.	3.7	2
94	Esophageal cancer: Epidemiology, risk factors and screening. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 535-547.	2.2	64
95	m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 190.	17.0	36
96	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 745769.	4.8	3
97	Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. <i>Nature Communications</i> , 2021, 12, 6770.	12.8	105
98	m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. <i>BMC Medicine</i> , 2021, 19, 284.	5.5	23
99	Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 782106.	4.8	0
100	Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 780461.	3.7	28
101	Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. <i>Lancet Public Health</i> , The, 2021, 6, e877-e887.	10.0	69
102	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110619.	3.2	3
103	Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 11, 0-0.	2.8	2
104	Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 4423-4444.	2.8	6
105	An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer. <i>Cancer Cell International</i> , 2021, 21, 691.	4.1	5
106	Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study. <i>BMC Cancer</i> , 2021, 21, 1323.	2.6	20
107	Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. <i>Cancer Cell International</i> , 2021, 21, 652.	4.1	11
108	ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC. <i>Frontiers in Immunology</i> , 2021, 12, 788985.	4.8	10

#	ARTICLE	IF	CITATIONS
109	The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. <i>Cancer Letters</i> , 2020, 470, 95-105.	7.2	193
110	Raman spectroscopy as a potential diagnostic tool to analyse biochemical alterations in lung cancer. <i>Analyst</i> , The, 2020, 145, 385-392.	3.5	30
111	The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes. <i>International Journal of Cancer</i> , 2020, 147, 958-966.	5.1	7
112	Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study. <i>Cancer Medicine</i> , 2020, 9, 816-823.	2.8	6
113	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. <i>Nature Communications</i> , 2020, 11, 4878.	12.8	27
114	&lt;p&gt;Solid Nodule Appearance as a Predictor of Tumor Spread Through Air Spaces in Patients with Lung Adenocarcinoma: A Propensity Score Matching Study&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 8197-8207.	1.9	4
115	ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells. <i>Cell Death and Disease</i> , 2020, 11, 853.	6.3	21
116	Collision tumor of the esophagus: a report of five cases. <i>Chinese Medical Journal</i> , 2020, 133, 2386-2388.	2.3	2
117	ECCParaCorp: a cross-lingual parallel corpus towards cancer education, dissemination and application. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 122.	3.0	4
118	Combined detection of aneuploid circulating tumorâ€derived endothelial cells and circulating tumor cells may improve diagnosis of early stage nonâ€smallâ€cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e128.	4.0	22
119	Initial results from a multi-center population-based cluster randomized trial of esophageal and gastric cancer screening in China. <i>BMC Gastroenterology</i> , 2020, 20, 398.	2.0	21
120	Response to comment on â€Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinomaâ€™. <i>Cancer Letters</i> , 2020, 494, 5-6.	7.2	0
121	Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients. <i>Annals of Translational Medicine</i> , 2020, 8, 822-822.	1.7	23
122	Clinical development of immuno-oncology in China. <i>Lancet Oncology</i> , The, 2020, 21, 1013-1016.	10.7	16
123	Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma. <i>International Immunopharmacology</i> , 2020, 87, 106802.	3.8	8
124	Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma. <i>Oncolmmunology</i> , 2020, 9, 1824641.	4.6	38
125	The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer. <i>Cell Death and Disease</i> , 2020, 11, 933.	6.3	9
126	An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 182.	17.1	21



#	ARTICLE	IF	CITATIONS
127	Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 193.	8.6	46
128	Lung Cancer in People's Republic of China. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1567-1576.	1.1	114
129	Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723.	27.0	1,042
130	Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 59, 102959.	6.1	51
131	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. <i>BMC Medicine</i> , 2020, 18, 232.	5.5	15
132	A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e156.	4.0	19
133	Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 559568.	2.8	12
134	Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. <i>Npj Precision Oncology</i> , 2020, 4, 32.	5.4	27
135	Epidemiology of Thyroid Cancer: Incidence and Mortality in China, 2015. <i>Frontiers in Oncology</i> , 2020, 10, 1702.	2.8	41
136	Managing a radiotherapy center safely and efficiently using risk-adaptive strategies during coronavirus disease pandemic: Experience from national cancer center of China. <i>Radiotherapy and Oncology</i> , 2020, 148, 243-244.	0.6	6
137	Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 681-694.	4.4	7
138	Health-related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ-5D: A multicenter cross-sectional study. <i>Thoracic Cancer</i> , 2020, 11, 1076-1089.	1.9	11
139	The Prognostic Significance of Metabolic Syndrome and a Related Six-lncRNA Signature in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 61.	2.8	26
140	Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. <i>Cancer Letters</i> , 2020, 479, 31-41.	7.2	57
141	Development and validation of an immune-related prognostic signature in lung adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5960-5975.	2.8	79
142	Development of a predictive nomogram for cause-specific mortality in surgically resected early-stage oesophageal cancer: a Surveillance, Epidemiology, and End Results (SEER) analysis. <i>Journal of Thoracic Disease</i> , 2020, 12, 2583-2594.	1.4	5
143	Cancer registration in China and its role in cancer prevention and control. <i>Lancet Oncology</i> , The, 2020, 21, e342-e349.	10.7	272
144	Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 821-841.	2.5	22

#	ARTICLE	IF	CITATIONS
145	Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics. <i>DNA and Cell Biology</i> , 2020, 39, 631-644.	1.9	15
146	Postoperative Radiotherapy in Pathological T2â€“3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. <i>Oncologist</i> , 2020, 25, e701-e708.	3.7	23
147	Loss of SUSD2 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma. <i>Journal of Cancer</i> , 2020, 11, 1648-1656.	2.5	6
148	lncTUG1/miR-144-3p affect the radiosensitivity of esophageal squamous cell carcinoma by competitively regulating c-MET. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 7.	8.6	38
149	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 816-826.	1.1	272
150	Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population. <i>Cancer Medicine</i> , 2020, 9, 3983-3994.	2.8	13
151	Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma. <i>Cancer Letters</i> , 2020, 483, 46-58.	7.2	28
152	Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration. <i>Journal of Cancer</i> , 2020, 11, 3858-3870.	2.5	22
153	High <sc>MAF</sc> of <sc>i>EGFR</i> mutations and high ratio of <sc>T790M</sc> sensitizing mutations</sc> in <sc>ctDNA</sc> predict better thirdâ€“generation <sc>TKI</sc> outcomes. <i>Thoracic Cancer</i> , 2020, 11, 1503-1511.	1.9	9
154	Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state. <i>Cancer Science</i> , 2020, 111, 1876-1886.	3.9	16
155	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 278.	2.6	7
156	Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 598437.	2.8	17
157	Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. <i>Frontiers in Genetics</i> , 2020, 11, 617174.	2.3	12
158	The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1209-1219.	6.4	56
159	Treatment outcomes of patients with tracheobronchial mucoepidermoid carcinoma compared with those with adenoid cystic carcinoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1888-1895.	1.0	10
160	Availability of anticancer biosimilars in 40 countries. <i>Lancet Oncology</i> , The, 2020, 21, 197-201.	10.7	13
161	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of nonâ€“smallâ€“cell lung cancer: A multicenter in vitro diagnostic clinical trial. <i>Cancer Science</i> , 2020, 111, 1739-1749.	3.9	11
162	Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 768-781.	3.0	33

#	ARTICLE	IF	CITATIONS
163	A study protocol of population-based cancer screening cohort study on esophageal, stomach and liver cancer in rural China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 540-546.	2.2	7
164	Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 580005.	3.7	9
165	No expenditure difference among patients with liver cancer at stage I-IV: Findings from a multicenter cross-sectional study in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 516-529.	2.2	10
166	Burchellin and its stereoisomers: total synthesis, structural elucidation and antiviral activity. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 9081-9087.	2.8	1
167	High S phase kinase-associated protein 2 expression is a potential prognostic biomarker for glioma. <i>Oncology Letters</i> , 2020, 20, 2788-2796.	1.8	6
168	Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection. <i>Oncolmmunology</i> , 2019, 8, e1625689.	4.6	37
169	Esophageal Squamous Cell Carcinoma Involving the Lip, Back and Hip. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1672-1674.	1.1	1
170	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. <i>Radiotherapy and Oncology</i> , 2019, 140, 159-166.	0.6	16
171	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3188-3196.	2.5	54
172	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
173	Tracheobronchial Adenoid Cystic Carcinoma: 50-Year Experience at the National Cancer Center, China. <i>Annals of Thoracic Surgery</i> , 2019, 108, 873-882.	1.3	26
174	Changes in clinical trials of cancer drugs in mainland China over the decade 2009-2018: a systematic review. <i>Lancet Oncology, The</i> , 2019, 20, e619-e626.	10.7	63
175	Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. <i>Frontiers in Oncology</i> , 2019, 9, 1047.	2.8	14
176	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3055-3065.	2.5	24
177	Associations of PCK1 promoter hypomethylation and PCK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis. <i>Cancer Communications</i> , 2019, 39, 1-17.	9.2	23
178	Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. <i>The Lancet Global Health</i> , 2019, 7, e257-e269.	6.3	175
179	Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. <i>Cancer Letters</i> , 2019, 459, 86-99.	7.2	34
180	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2890-2898.	1.5	28

#	ARTICLE	IF	CITATIONS
181	Knockdown of <i>KLF5</i> promotes cisplatin-induced cell apoptosis via regulating DNA damage checkpoint proteins in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1069-1077.	1.9	18
182	Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 571-578.	4.4	39
183	PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing. <i>Cancer Medicine</i> , 2019, 8, 2429-2441.	2.8	26
184	Ultrasound for Breast Cancer Screening in High-Risk Women: Results From a Population-Based Cancer Screening Program in China. <i>Frontiers in Oncology</i> , 2019, 9, 286.	2.8	18
185	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 761-768.	1.9	63
186	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 50 5</i>	17.0	69
187	Lung cancer imaging methods in China from 2005 to 2014: A national, multicenter study. <i>Thoracic Cancer</i> , 2019, 10, 708-714.	1.9	4
188	Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1123.	2.8	21
189	Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity. <i>Journal of Translational Medicine</i> , 2019, 17, 430.	4.4	5
190	International expert consensus on the management of bleeding during VATS lung surgery. <i>Annals of Translational Medicine</i> , 2019, 7, 712-712.	1.7	23
191	The TGF $\beta$ <sup>2</sup> -Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis. <i>Frontiers in Oncology</i> , 2019, 9, 1340.	2.8	6
192	Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey. <i>Lung Cancer</i> , 2019, 128, 91-100.	2.0	81
193	Acetyl-macrocyclin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762. <i>Toxicology and Applied Pharmacology</i> , 2019, 365, 71-83.	2.8	10
194	Participation and yield of a population-based colorectal cancer screening programme in China. <i>Gut</i> , 2019, 68, 1450-1457.	12.1	222
195	Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. <i>International Journal of Cancer</i> , 2019, 144, 2972-2984.	5.1	38
196	Survival-associated alternative splicing signatures in esophageal carcinoma. <i>Carcinogenesis</i> , 2019, 40, 121-130.	2.8	66
197	PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. <i>Human Pathology</i> , 2019, 84, 291-298.	2.0	18
198	Amotnib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 95-95.	1.6	12

#	ARTICLE	IF	CITATIONS
199	Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, 319-328.	1.4	10
200	Medical expenditures for colorectal cancer diagnosis and treatment: A 10-year high-level-hospital-based multicenter retrospective survey in China, 2002-2011. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 825-837.	2.2	16
201	Sequencing a super multiple synchronous lung cancer reveals a novel variant in driver gene ARID1B. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, e185-e191.	0.8	8
202	Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. <i>Cancer Letters</i> , 2018, 423, 9-15.	7.2	38
203	Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. <i>The Lancet Global Health</i> , 2018, 6, e555-e567.	6.3	907
204	TGF- $\beta$ 2-induced NKILA inhibits ESCC cell migration and invasion through NF- $\kappa$ B/MMP14 signaling. <i>Journal of Molecular Medicine</i> , 2018, 96, 301-313.	3.9	44
205	Breast cancer risk factors and mammographic density among high-risk women in urban China. <i>Npj Breast Cancer</i> , 2018, 4, 3.	5.2	51
206	Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 469-481.	2.3	3
207	Medical expenses of urban Chinese patients with stomach cancer during 2002-2011: a hospital-based multicenter retrospective study. <i>BMC Cancer</i> , 2018, 18, 435.	2.6	14
208	Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey. <i>Breast</i> , 2018, 39, 53-62.	2.2	25
209	Acetyl-macrocalin B, an <i>ent</i> -kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 609-621.	3.4	16
210	Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 R132H mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss. <i>Journal of Clinical Pathology</i> , 2018, 71, 702-707.	2.0	16
211	Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross-sectional study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 167-178.	1.1	45
212	The Society for Translational Medicine: indications and methods of percutaneous transthoracic needle biopsy for diagnosis of lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5538-5544.	1.4	17
213	Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition). <i>Journal of Thoracic Disease</i> , 2018, 10, 2481-2489.	1.4	37
214	Society for Translational Medicine Expert Consensus on the prevention and treatment of postoperative pulmonary infection in esophageal cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, 1050-1057.	1.4	8
215	Society for Translational Medicine Expert Consensus on the preoperative assessment of circulatory and cardiac functions and criteria for the assessment of risk factors in patients with lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5545-5549.	1.4	8
216	Long-term survival of the middle and lower thoracic esophageal cancer patients after surgical treatment through left or right thoracic approach. <i>Journal of Thoracic Disease</i> , 2018, 10, 2648-2655.	1.4	16

#	ARTICLE	IF	CITATIONS
217	Society for Translational Medicine expert consensus on training and certification standards for surgeons and assistants in minimally invasive surgery for lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5666-5672.	1.4	5
218	Sleep duration and the risk of cancer: a systematic review and meta-analysis including dose-response relationship. <i>BMC Cancer</i> , 2018, 18, 1149.	2.6	105
219	Solitary fibrous tumors of the pleura: A single center experience at National Cancer Center, China. <i>Thoracic Cancer</i> , 2018, 9, 1763-1769.	1.9	12
220	Waist Circumference Might Be a Predictor of Primary Liver Cancer: A Population-Based Cohort Study. <i>Frontiers in Oncology</i> , 2018, 8, 607.	2.8	18
221	The Society for Translational Medicine: the assessment and prevention of venous thromboembolism after lung cancer surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 3039-3053.	1.4	18
222	Society for Translational Medicine expert consensus on the use of antibacterial drugs in thoracic surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 6356-6374.	1.4	4
223	Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. <i>Cell Death and Disease</i> , 2018, 9, 759.	6.3	69
224	Cancer incidence and mortality in China, 2014. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 1-12.	2.2	759
225	Long non-coding RNA GAS5 is induced by interferons and plays an antitumor role in esophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 3157-3167.	2.8	22
226	Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. <i>Cancer Letters</i> , 2018, 430, 57-66.	7.2	92
227	The TGF $\beta$ <sup>2</sup> -induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling. <i>Cancer Letters</i> , 2018, 432, 156-168.	7.2	68
228	Aberrant methylation of EYA4 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2018, 109, 1811-1824.	3.9	26
229	Effect of the TGF $\beta$ <sup>2</sup> induced lncRNA TBILA on non-small cell lung cancer progression by regulating HGAL and binding with S100A7. <i>Journal of Clinical Oncology</i> , 2018, 36, e24203-e24203.	1.6	2
230	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 13920-13933.	1.8	60
231	Medical expenditure for liver cancer in urban China. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 163-170.	0.9	28
232	Comparison of short-term outcomes and three-year survival between total minimally invasive (MCK) and dual-incision esophagectomy. <i>Thoracic Cancer</i> , 2017, 8, 80-87.	1.9	16
233	Prognostic alternative mRNA splicing signature in non-small cell lung cancer. <i>Cancer Letters</i> , 2017, 393, 40-51.	7.2	214
234	The Impact of Postoperative Conformal Radiotherapy After Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1143-1151.	1.1	35

#	ARTICLE	IF	CITATIONS
235	Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF- $\kappa$ B/Snail pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 54.	8.6	116
236	Dumbbell-Shaped Jugular Foramen Tumors Extending to the Neck: Surgical Considerations Based on Imaging Findings. <i>World Neurosurgery</i> , 2017, 104, 14-23.	1.3	3
237	Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey. <i>Chinese Journal of Cancer</i> , 2017, 36, 41.	4.9	74
238	Cancer incidence and mortality in China, 2013. <i>Cancer Letters</i> , 2017, 401, 63-71.	7.2	352
239	The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous cell carcinoma: a meta-analysis. <i>Cancer Medicine</i> , 2017, 6, 54-66.	2.8	15
240	Effect of socioeconomic status on stage at diagnosis of lung cancer in a hospital-based multicenter retrospective clinical epidemiological study in China, 2005-2014. <i>Cancer Medicine</i> , 2017, 6, 2440-2452.	2.8	14
241	The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. <i>British Journal of Cancer</i> , 2017, 117, 1405-1411.	6.4	26
242	RNA editing is induced by type I interferon in esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770854.	1.8	10
243	Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. <i>Oncol Immunology</i> , 2017, 6, e1356147.	4.6	69
244	The therapeutic effects of Longikaurin A, a natural ent-kauranoid, in esophageal squamous cell carcinoma depend on ROS accumulation and JNK/p38 MAPK activation. <i>Toxicology Letters</i> , 2017, 280, 106-115.	0.8	8
245	Exosomes: New players in cancer. <i>Oncology Reports</i> , 2017, 38, 665-675.	2.6	122
246	High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 84.	8.6	54
247	Long-term outcomes of 307 patients after complete thymoma resection. <i>Chinese Journal of Cancer</i> , 2017, 36, 46.	4.9	15
248	Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002-2011). <i>Chinese Journal of Cancer</i> , 2017, 36, 73.	4.9	27
249	The Society for Translational Medicine: clinical practice guidelines for mechanical ventilation management for patients undergoing lobectomy. <i>Journal of Thoracic Disease</i> , 2017, 9, 3246-3254.	1.4	21
250	The Society for Translational Medicine: clinical practice guidelines for the postoperative management of chest tube for patients undergoing lobectomy. <i>Journal of Thoracic Disease</i> , 2017, 9, 3255-3264.	1.4	47
251	Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. <i>Chinese Journal of Cancer</i> , 2017, 36, 65.	4.9	55
252	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. <i>Oncotarget</i> , 2017, 8, 41102-41112.	1.8	10

#	ARTICLE	IF	CITATIONS
253	Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 1-10.	2.2	213
254	Experiences in the management of anastomotic leakages and analysis of the factors affecting leakage healing in patients with esophagogastric junction cancer. Journal of Thoracic Disease, 2017, 9, 386-391.	1.4	11
255	Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. Journal of Thoracic Disease, 2017, 9, 5267-5277.	1.4	12
256	KAT2A coupled with the $\hat{\pm}$ -KGDH complex acts as a histone H3 succinyltransferase. Nature, 2017, 552, 273-277.	27.8	301
257	Evaluating efficacy of screening for upper gastrointestinal cancer in China: a study protocol for a randomized controlled trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 294-302.	2.2	28
258	A Model Predicting Lymph Node Status for Patients with Clinical Stage T1aNO-2M0 Nonsmall Cell Lung Cancer. Chinese Medical Journal, 2017, 130, 398-403.	2.3	9
259	Prognostic value of preoperative neutrophil-lymphocyte ratio is superior to platelet-lymphocyte ratio for survival in patients who underwent complete resection of thymic carcinoma. Journal of Thoracic Disease, 2016, 8, 1487-1496.	1.4	13
260	Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma. Journal of Thoracic Disease, 2016, 8, 2464-2472.	1.4	10
261	The impact of operative approaches on outcomes of middle and lower third esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2016, 8, 3588-3595.	1.4	8
262	A propensity matched comparison of effects between video assisted thoracoscopic single-port, two-port and three-port pulmonary resection on lung cancer. Journal of Thoracic Disease, 2016, 8, 1469-1476.	1.4	18
263	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1565-1573.	1.1	32
264	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Molecular Cell, 2016, 61, 705-719.	9.7	319
265	Transcriptome profiling of lncRNA and co-expression networks in esophageal squamous cell carcinoma by RNA sequencing. Tumor Biology, 2016, 37, 13091-13100.	1.8	36
266	Characteristics and Surgical Outcomes for Primary Malignant Melanoma of the Esophagus. Scientific Reports, 2016, 6, 23804.	3.3	31
267	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. Oncotarget, 2016, 7, 55211-55221.	1.8	13
268	Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing. Oncotarget, 2016, 7, 81715-81726.	1.8	7
269	A Matched Comparison Study of Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early-stage Nonsmall Cell Lung Cancer. Chinese Medical Journal, 2015, 128, 2731-2735.	2.3	47
270	Patterns and predictors of recurrence after radical resection of thymoma. Radiotherapy and Oncology, 2015, 115, 30-34.	0.6	23



#	ARTICLE	IF	CITATIONS
271	Transcriptome profiling of esophageal squamous cell carcinoma reveals a long noncoding RNA acting as a tumor suppressor. <i>Oncotarget</i> , 2015, 6, 17065-17080.	1.8	39
272	Updated experiences with minimally invasive McKeown esophagectomy for esophageal cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 12873.	3.3	43
273	Annual report on status of cancer in China, 2011. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2015, 27, 2-12.	2.2	405
274	LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. <i>Gut</i> , 2014, 63, 1700-1710.	12.1	385
275	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e91388.	2.5	39
276	Challenges to effective cancer control in China, India, and Russia. <i>Lancet Oncology</i> , The, 2014, 15, 489-538.	10.7	411
277	Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. <i>Nature Genetics</i> , 2014, 46, 1001-1006.	21.4	148
278	Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma. <i>Annals of Thoracic Surgery</i> , 2014, 98, 513-519.	1.3	46
279	Comparative study of minimally invasive versus open esophagectomy for esophageal cancer in a single cancer center. <i>Chinese Medical Journal</i> , 2014, 127, 747-52.	2.3	18
280	Over-expression of small ubiquitin-like modifier proteases 1 predicts chemo-sensitivity and poor survival in non-small cell lung cancer. <i>Chinese Medical Journal</i> , 2014, 127, 4060-5.	2.3	5